Psilocybe cubensis
Psilocybe cubensis
Psilocybe cubensis is a dung-loving saprotrophic fungus native to tropical and subtropical regions worldwide, producing the psychedelic alkaloid psilocybin in its fruiting bodies. It is among the most widely cultivated mushrooms in the world and the most researched psilocybin-producing species in contemporary science. Its ease of indoor cultivation, broad geographic range, and well-documented chemistry have made it the de facto model organism for psilocybin research.
Psilocybe cubensis (Earle) Singer 1949 — Family Hymenogastraceae — Order Agaricales
Psilocybe cubensis occupies a unique position in mycology: simultaneously a scientifically significant model organism, a species with deep ethnomycological roots in Mesoamerican ritual traditions, and the subject of a rapidly expanding body of clinical research. Its golden-brown caps and telltale blue bruising are recognised the world over. It is saprotrophic — meaning it obtains nutrients by breaking down dead organic matter, principally herbivore dung — which is precisely why it can be cultivated without a living host tree, unlike mycorrhizal species. This biology, together with its tractable genetics and well-characterised alkaloid chemistry, has placed Psilocybe cubensis at the centre of both applied cultivation and rigorous scientific investigation.
What Is Psilocybe cubensis?
Psilocybe cubensis is a medium-sized agaric (gill-bearing mushroom) in the family Hymenogastraceae, most readily identified by its golden-brown to cinnamon cap, dark purplish-brown spore print, membranous ring on the stipe, and — most diagnostically — its pronounced blue bruising when any part of the tissue is damaged. The blueing results from the rapid oxidation of psilocin, a dephosphorylated form of psilocybin, providing a visible colour-change indicator of psilocybin presence that is widely used in field identification.
The species is commonly called "magic mushrooms," "gold caps," "golden tops," "cubes," and "shrooms," though none of these names are taxonomically precise — all of them are applied to other psilocybin-containing fungi as well. Regional names add further variety: "golden top" and "gold cap" in Australia, "San Ysidro" in the United States and Mexico, "golden teacher" in South Africa, and hed keequai ("mushroom that appears after the water buffalo defecates") in Thailand. For the purposes of a species guide, none of these informal names functions as a stable anchor; the scientific name Psilocybe cubensis — alongside the generic phrase "magic mushrooms" — reflects actual search behaviour and should serve as the primary keyword pairing.
Taxonomy and Nomenclature of Psilocybe cubensis
The species was first formally described by the American botanist Franklin Sumner Earle in 1906 from a Cuban specimen, under the name Stropharia cubensis — the genus epithet "cubensis" recording its type locality. Additional synonyms were created from independent collections in different countries before their identity was recognised: Naematoloma caerulescens Patouillard 1907 (from Tonkin, Vietnam) and Stropharia cyanescens Murrill 1941 (from Florida). All three names were united under Psilocybe cubensis when Rolf Singer transferred the species to Psilocybe in 1949.
| Rank | Classification |
|---|---|
| Kingdom | Fungi |
| Phylum | Basidiomycota |
| Class | Agaricomycetes |
| Order | Agaricales |
| Family | Hymenogastraceae |
| Genus | Psilocybe (Fr.) P.Kumm. |
| Species | Psilocybe cubensis (Earle) Singer 1949 |
| Basionym | Stropharia cubensis Earle 1906 |
| MycoBank | See MycoBank directly; sister species P. subcubensis carries MB #321955 |
The genus name Psilocybe derives from the Greek psilos (bare) + kubê (head), referencing the smooth, bare appearance of the cap. Modern multi-gene phylogenies have moved Psilocybe from the former Strophariaceae into Hymenogastraceae — a family placement now accepted by GBIF, MycoBank, and Index Fungorum, though older regional field guides and some databases may still list the family as Strophariaceae.
A closely related and easily confused sister species, Psilocybe subcubensis, has near-identical macroscopic morphology and overlapping distribution; its key distinction is smaller basidiospores. Mislabelling between these two species is a known problem in herbarium records and field reports, which complicates any attempt to treat distribution data or potency records as entirely clean.
How to Identify Psilocybe cubensis
Field identification of Psilocybe cubensis relies on a combination of macroscopic characters, with blue bruising serving as the single most widely used diagnostic feature. A spore print and, where possible, microscopic examination substantially increase confidence, particularly in regions where lookalike species co-occur.
Microscopic Features
Basidiospores (the sexual spores produced on club-shaped basidia) are subellipsoid, 11.5–17 × 8–11 µm, thick-walled, and bear a distinct germ pore — a thin-walled circular opening through which the germination tube emerges. The Q ratio (length ÷ width, a measure of elongation) falls approximately 1.3–1.8. Basidia are mostly 4-spored, though 2- and 3-spored basidia occur. Both pleurocystidia (sterile cells on the gill face) and cheilocystidia (sterile cells on the gill edge) are present. The combination of thick-walled, germ-pored spores and the purplish-brown print is the most reliable microscopic confirmation.
Developmental Changes
Young buttons show a strongly convex to conic cap with the partial veil (velum partiale) intact beneath the cap margin. As the cap expands, the veil tears and leaves a persistent annulus on the stipe. The ring surface and upper stipe often become stained dark by falling spores as the fruit body matures. Cap colour is significantly hydration-dependent: in wet conditions caps appear darker and viscid, while dry specimens are conspicuously paler and less shiny — a character that creates identification uncertainty for collectors unfamiliar with the species.
Lookalike Species
The most important lookalike — morphologically near-identical, sharing the same habitat, golden-brown cap, and blue bruising. Distinguished by smaller spores: typically 9–12 × 6–7 µm versus 11.5–17 × 8–11 µm in P. cubensis. Mislabelling between these two species is well documented. Microscopy is required for reliable separation.
Several Panaeolus species (including P. cinctulus and P. cyanescens, the latter itself psychoactive) occur on dung in similar habitats. They generally lack the viscid cap surface, have a different cap shape profile, and produce black (not purplish-brown) spore prints. Some species may show faint blueing. Check spore print colour and bruising intensity carefully.
Historically placed in the same genus, some Stropharia share the ringed stipe and purplish-brown spore print. They are not blue-bruising and do not contain psilocybin. The presence of strong blue bruising on all tissues, on damage, distinguishes P. cubensis from non-psychoactive Stropharia.
"LBM" (little brown mushroom) — a catch-all for small brown agarics — is a practical risk category in dung habitats. Conocybe, Pholiotina, and similar genera can fruit on or near dung and can contain amatoxins. These do not blue-bruise and typically produce a rusty-brown spore print. Never consume a dung mushroom without confirming blue bruising and a dark purplish-brown — not rust-brown — spore print.
Genetics and Phylogeny of Psilocybe cubensis
Molecular work on Psilocybe and broader Agaricales most commonly employs ITS rDNA (Internal Transcribed Spacer — the standard fungal barcode) as the primary identification marker, supplemented by LSU and SSU ribosomal sequences plus protein-coding loci — RPB1 and RPB2 (the first and second largest subunits of RNA polymerase II) and beta-tubulin — for deeper phylogenetic resolution. ITS reliably separates P. cubensis from distantly related Psilocybe species, but closely related taxa such as P. subcubensis have sufficiently similar ITS sequences that multi-locus datasets are recommended for robust separation, particularly when verifying culture identities of hobbyist strains.
Multi-gene phylogenies consistently place psilocybin-producing Psilocybe within Hymenogastraceae, forming a distinct clade within Agaricales that is fully separated from the former Stropharia sensu lato of Strophariaceae. This clade has been used as a model system for studying the psilocybin biosynthetic gene cluster — a set of four key enzymes: tryptophan decarboxylase, methyltransferase, hydroxylase, and kinase — whose evolution across Psilocybe has been the subject of comparative genomic analysis.
At least one whole-genome assembly for P. cubensis or a closely allied strain is available from psilocybin biosynthesis research; specific NCBI accessions should be verified at the time of writing, as the literature notes that genomic resources underlie recent comparative analyses of psilocybin pathway evolution. Population-level genetic data are sparse: the extent to which informally named hobbyist "strains" represent distinct genetic lineages versus phenotypic variants under common selection remains largely uncharacterised.
Ecology and Distribution of Psilocybe cubensis
Psilocybe cubensis is saprotrophic and coprophilous — it obtains nutrition by decomposing dead organic matter, specifically the dung of herbivores. In plain terms: this species feeds on the nutrient-rich, partially digested plant material in cattle, horse, and water buffalo dung. It does not form partnerships with living tree roots (unlike ectomycorrhizal species) and does not parasitise its host. This saprotrophic biology is the direct reason P. cubensis can be cultivated on sterilised, nutrient-rich substrates indoors, without any living host organism.
| Region | Range Notes | Season (approx.) |
|---|---|---|
| Gulf Coast & SE United States | Florida, Texas, Gulf states; pastures with grazing cattle | Feb–Nov |
| Mexico & Central America | Widespread from Mexico through Costa Rica, Panama, Belize | Year-round with rain |
| Caribbean & South America | Multiple islands; Argentina, Brazil, Colombia, and broadly | Wet season windows |
| Southeast Asia | Thailand, Vietnam, Cambodia, Malaysia; linked to water buffalo husbandry | Monsoon season |
| Indian subcontinent | India; dung-associated occurrence documented | Monsoon season |
| Australia & Pacific | Australia (linked to cattle introduction), Fiji; distribution follows livestock grazing | Nov–Apr (southern hemisphere) |
The species' modern global distribution partly reflects the spread of European cattle ranching. In Australia, for example, the introduction of domestic cattle in the 18th century provided the substrate necessary for P. cubensis to establish — its occurrence there is broadly linked to agricultural expansion rather than pre-existing native range. Fruiting bodies typically emerge directly on or immediately adjacent to dung pats in open pastures, particularly after rainy periods with sustained high humidity. The microhabitat preference is grazed grassland rather than forest, distinguishing it ecologically from many other Psilocybe species.
No IUCN Red List assessment or major conservation concern exists for P. cubensis. As a common, widely introduced species associated with a globally pervasive substrate, it is not a conservation target in any jurisdiction; its legal relevance is overwhelmingly as a controlled psychoactive organism rather than as a species requiring protection.
Cultivating Psilocybe cubensis
Psilocybe cubensis is one of the most widely cultivated mushrooms in the world. Its saprotrophic biology, tolerance of common agricultural substrates, and relatively forgiving temperature range make it considerably more accessible to indoor cultivation than mycorrhizal species — or even many saprotrophic wood-decomposers with narrower nutritional requirements. The following sections distinguish between peer-reviewed cultivation data and hobbyist or vendor-reported practices.
Substrates
Peer-reviewed literature identifies P. cubensis as adapted to low C:N (carbon-to-nitrogen) dung substrates, in contrast to wood-decomposing Psilocybe species that require higher C:N ratios. Published work shows it responds strongly to vitamin and mineral supplementation — more so than the wood-loving P. azurescens in comparative media trials. Commonly used substrates in practice include pasteurised mixtures of manure (cow or horse), straw, coconut coir (the fibrous material from coconut husks), vermiculite (a mineral used for moisture retention), and cereal grains (rye, wheat, brown rice) as spawn.
Quantitative biological efficiency (BE — the mass of fresh mushrooms produced per mass of dry substrate) data from peer-reviewed sources are limited. The 2025 cultivation review explicitly notes that systematic, replicated yield experiments varying substrate composition are sparse, and that BE figures in circulation are largely derived from hobbyist reports or vendor data rather than controlled scientific trials.
Spawn run: ~80–82 °F substrate temperature (~27–28 °C); ~90% relative humidity; CO₂ tolerance reported at 5,000–10,000 ppm. Fruiting phase: ~68–72 °F (20–22 °C); high relative humidity; frequent fresh-air exchanges; CO₂ kept below ~1,000 ppm to avoid elongated stipes and reduced cap development. Multi-flush production — several waves of fruiting over weeks — is well attested in practice, though peer-reviewed data on flush-by-flush yield and psilocybin content across flushes are identified as a research gap.
Agar Culture
Peer-reviewed experimental work has compared P. cubensis with other Psilocybe species on semi-solid media. Mycelium was germinated from spores in sterile water and transferred to quarter-strength PDA (potato dextrose agar) or water agar for subculture. Carbon source, nitrogen source, C:N ratio, and vitamin content significantly influenced colony density and morphology, with P. cubensis responding more strongly to added vitamins and minerals than a wood-loving P. azurescens genotype — consistent with its adaptation to nutrient-rich dung substrates.
On standard PDA, P. cubensis colonies develop dense cottony to rhizomorphic (root-like, branching) white mycelium, often with sectoring — the appearance of distinct zones of different morphology within a single colony — which reflects genetic heterogeneity and is a commonly observed characteristic on agar. Optimal growth occurs at mid-20s °C. Very high mineral concentrations can inhibit or damage mycelium. Precise mm/day growth rates and optimal pH values are not consistently reported in the literature and vary by medium and genotype.
Liquid Culture
Early psilocybin research often used submerged liquid culture of P. cubensis mycelium, though the focus in recent years has shifted toward solid substrate fruiting body production. Liquid cultures typically use sugar-rich media — glucose or sucrose solutions, malt-based broths — and can produce significant mycelial biomass. Published growth curves (g dry weight/L/day) for named strains are rarely reported; the 2025 cultivation review identifies this as a gap in quantitative data.
In practical terms, liquid cultures of P. cubensis are used for: inoculating grain or bulk substrates as liquid spawn; expanding clean agar isolates; and producing mycelial biomass for pharmacological or biochemical research including psilocybin production assays. Liquid cultures are vulnerable to bacterial contamination and fast-growing moulds — contamination control and reliable sterile technique are the primary practical challenges, though formal species-specific contamination surveys are absent from the literature.
Strain Variation
Dozens of named "strains" circulate in the hobby and research world — Golden Teacher, B+, Blue Meanie, Creeper, Texas, and many others — selected by growers for morphological traits or perceived potency. A 2024 LC-MS/MS (liquid chromatography–mass spectrometry) study developed a validated analytical method and quantified psilocybin and psilocin in five named strains (Blue Meanie, Creeper, B+, Texas, and a generic Cubensis), demonstrating statistically significant variation in alkaloid content among strains. This confirms that real biochemical variability exists within the species, though whether it maps onto distinct genetic lineages or represents phenotypic variation within a single gene pool is unresolved. Robust comparative data on growth rate, yield, and environmental preferences among strains are identified as a significant research gap.
Obtain Clean Culture
Start from spores germinated on quarter-strength PDA or water agar, or from a vendor-supplied liquid culture. Confirm identity before proceeding.
Expand on Agar
Transfer to nutrient agar (PDA or MEA). Select rhizomorphic sectors for transfer; avoid sectors showing unusual colouration or contamination signs. Optimal temperature: mid-20s °C.
Liquid Culture / Grain Spawn
Transfer agar colonised sectors to liquid culture or directly to sterilised grain (rye, wheat). Liquid culture is used as rapid-inoculation liquid spawn for bulk substrate.
Bulk Substrate Colonisation
Inoculate pasteurised dung/straw, coco coir, or similar low C:N substrate. Maintain high humidity and minimal light during colonisation. Full colonisation precedes fruiting trigger.
Fruiting Conditions
Introduce fresh air exchanges (lowering CO₂), light, and high humidity. Primordia (pin-stage fruit bodies) form in response to CO₂ reduction and humidity gradient; harvest before veils fully tear.
Chemistry of Psilocybe cubensis
The chemistry of Psilocybe cubensis is dominated by two tryptamine alkaloids (nitrogen-containing aromatic compounds derived from the amino acid tryptophan): psilocybin and psilocin. All published chemistry derives from fruiting body material unless otherwise noted.
The primary psychoactive compound. Maximum content in P. cubensis reported at approximately 2.02% dry weight — among the highest recorded in the genus. Content varies significantly by strain. Acts as a prodrug: dephosphorylated to psilocin in the body. Evidence level: human clinical data
The active metabolite of psilocybin; also present directly in fruiting bodies. The unstable oxidation of psilocin to blue-coloured quinone products is responsible for the diagnostic blue bruising. Co-quantified with psilocybin in the 2024 LC-MS/MS validated method; varies by strain. Evidence level: human clinical data
Minor tryptamine co-metabolites present in Psilocybe species. Pharmacological contributions to the overall effect profile of whole mushrooms (versus pure psilocybin) are not well characterised. Species-specific quantification in P. cubensis is sparse in the peer-reviewed record. Evidence level: structural / limited
Reported in reviews of Psilocybe chemistry, but biological activities remain unclear. It is not always confirmed whether these specific compounds are present in P. cubensis versus other Psilocybe species — source-checking is required before attributing them to this species. Evidence level: limited / extrapolated
Various phenolic compounds and organic acids described in Psilocybe genus reviews. Direct evidence from P. cubensis-specific assays is limited; antioxidant or other bioactivity claims for this species are largely extrapolated from other genera or from Psilocybe as a group. Evidence level: extrapolated from genus
No published GC-MS or GC-olfactometry studies have definitively identified the volatile compounds responsible for P. cubensis' farinaceous odour or its characteristic blue colour changes. The compound(s) responsible for these sensory traits remain unidentified in published analytical chemistry. This is an open research gap.
Safety, Toxicity, and Clinical Evidence for Psilocybe cubensis
Psilocybe cubensis is not associated with classical hepatotoxic (liver-damaging) mushroom poisoning syndromes. It does not contain amatoxins, phallotoxins, or orellanine. Its primary risks are psychological rather than organ-toxic: significant anxiety, dysphoria ("bad trips"), and psychological distress; in rare cases, self-harm or risky behaviour during acute intoxication. Physiological effects in healthy adults include transient increases in blood pressure and heart rate, nausea, and dizziness — generally self-limited, but potentially problematic in individuals with cardiovascular disease or psychiatric vulnerability.
Psilocybin itself is not considered neurotoxic in humans at therapeutic or typical recreational doses. Modern clinical trials with pharmaceutical-grade synthetic psilocybin report acceptable safety profiles in controlled settings, though repeated high-dose use outside medical supervision is insufficiently characterised.
Human Clinical Evidence
The vast majority of human clinical data concerns pharmaceutical-grade synthetic psilocybin — not whole P. cubensis fruiting bodies. Extrapolating clinical outcomes directly to mushroom consumption involves assumptions about dose equivalence, compositional stability between batches, and the contributions of minor alkaloids (baeocystin, norbaeocystin) that are not present in purified preparations.
A Phase 2a randomised, double-blind, placebo-controlled trial registered in 2024 (ClinicalTrials.gov NCT06898606) represents the most directly relevant ongoing study: it evaluates 3 g of standardised psilocybin mushrooms (likely P. cubensis) with or without concurrent fluoxetine 20 mg/day in adults with treatment-resistant major depressive disorder. Each participant receives one psychedelic-assisted session with 3 g of mushrooms, with batch LC-MS assay to quantify psilocybin/psilocin content; primary outcomes centre on changes in Montgomery–Åsberg Depression Rating Scale (MADRS) scores. Results have not been published. trial ongoing
At present there is no published body of randomised trials explicitly administering identified P. cubensis fruiting bodies and reporting species-specific outcomes. Any clinical claims in a species guide should clearly attribute evidence to psilocybin-the-molecule, not to P. cubensis-the-organism, and should note the distinction between controlled clinical dosing and uncontrolled self-administration.
Ethnomycological History of Psilocybe cubensis
Psilocybin-containing mushrooms have deep roots in Mesoamerican indigenous culture, where they were used in religious and healing rituals long before European contact. Archaeological and ethnographic records describe "teonanácatl" — the sacred mushroom — in Aztec and other Mesoamerican cultures, and historical accounts from the 16th century document the ceremonial use of mushrooms with visionary effects.
An important nuance: these historical records describe ritual use of Psilocybe broadly, not P. cubensis specifically. The species most prominently documented in pre-Columbian and colonial Mesoamerican contexts include P. aztecorum, P. mexicana, and others. Psilocybe cubensis appears to have gained its current global prominence primarily as a cultivated species in the second half of the 20th century, driven by its ease of indoor production. Its role as a clearly documented pre-Columbian ritual species — as distinct from Psilocybe species generally — is not well established.
In contemporary ethnomycology, P. cubensis is one of the most commonly used psychedelic mushroom species worldwide, both in underground spiritual communities and in non-clinical use, largely because of its ease of home cultivation and moderate, controllable potency. This modern folk tradition is reflected in the proliferation of named strain lore, regional common names, and DIY cultivation subculture. No commercial supplement formulations using P. cubensis specifically (as opposed to generic "mushroom extracts") are documented in peer-reviewed sources.
What Makes Psilocybe cubensis Unusual?
A Dung-Adapted Psychedelic
P. cubensis is one of the few coprophilous (dung-loving) psilocybin producers. Most psilocybin Psilocybe species specialise on wood, roots, or mossy grassland. This dung adaptation is directly responsible for its unusually strong response to vitamin and mineral supplementation in culture — a nutritional profile calibrated for one of nature's richest organic substrates.
A Quasi-Domesticated Species
The vast informal strain landscape — Golden Teacher, B+, Blue Meanie, and dozens more — represents an ongoing quasi-domestication process carried out almost entirely outside formal mycological taxonomy. It is among the richest "folk cultivar" traditions of any wild mushroom. LC-MS data confirm real underlying biochemical variation among strains, even without genetic characterisation.
Blue Bruising as Visible Diagnostic
The blue-staining reaction — psilocin oxidation to a blue quinone product on tissue damage — has become a practical field diagnostic for psilocybin producers. The mechanistic and ecological significance of psilocybin (defence? signalling? metabolic by-product?) remains genuinely unresolved in fungal biology, making this a visible marker of an open scientific question.
A Biosynthetic Gene Cluster Model
The four-enzyme psilocybin biosynthetic gene cluster (tryptophan decarboxylase, methyltransferase, hydroxylase, kinase) in Psilocybe has been studied across the genus in comparative genomics. P. cubensis genomic resources underlie this work, making the species central to understanding how a complex secondary metabolite pathway evolved and spread across fungi.
Cattle-Range Colonist
The global distribution of P. cubensis in Australia, parts of Asia, and beyond is partly a consequence of European cattle husbandry spreading a suitable substrate into regions it previously did not reach. The species' ecology is therefore entangled with the history of livestock agriculture in a way that makes its "natural" range difficult to define.
The First Whole-Mushroom Clinical Trial
The 2024 Phase 2a trial (NCT06898606) using 3 g of standardised P. cubensis mushrooms — with LC-MS batch verification — is among the first randomised controlled trials to administer whole mushrooms rather than synthetic psilocybin in a clinical setting, representing a methodological shift in how the species is studied in humans.
Psilocybe cubensis — Frequently Asked Questions
What makes Psilocybe cubensis blue when bruised?
The blue colour results from the rapid oxidation of psilocin when tissue is damaged. Psilocin — the dephosphorylated, active form of psilocybin — is enzymatically converted to a blue-coloured quinone product when cells are broken and their contents contact oxygen. This reaction is almost immediate and affects all parts of the mushroom including cap, gills, stipe, and flesh. It is one of the most reliable field indicators of psilocybin presence across the genus Psilocybe, though some other unrelated mushrooms also show blue bruising for different chemical reasons.
How much psilocybin does Psilocybe cubensis contain?
A recent chemical review reports maximum psilocybin content of approximately 2.02% dry weight in P. cubensis — among the highest recorded across the genus. However, psilocybin content varies significantly by strain, growing conditions, developmental stage at harvest, and drying method. A 2024 LC-MS/MS study confirmed statistically significant variation among five named strains. Psilocin content also varies and contributes to total potency alongside psilocybin. Any specific potency figure should be understood as a range, not a fixed value.
Why can Psilocybe cubensis be cultivated when other Psilocybe species cannot?
Psilocybe cubensis is saprotrophic — it obtains nutrients by decomposing dead organic matter (primarily herbivore dung) and does not require a living host. This means it can colonise and fruit on sterilised, nutrient-rich substrates indoors without any tree root partner. Many other Psilocybe species, such as P. azurescens, are wood-loving saprotrophs with different substrate requirements and can be harder to cultivate; the wood-decaying and dung-decomposing ecologies require different C:N ratios and nutrient profiles. None of the major Psilocybe species are ectomycorrhizal, which is the strongest barrier to cultivation in other mushroom genera.
What is the difference between Psilocybe cubensis and Psilocybe subcubensis?
The two species are morphologically near-identical — sharing the same golden-brown cap, blue bruising, dark purplish-brown spore print, and dung habitat. The primary distinguishing character is spore size: P. cubensis has larger spores (typically 11.5–17 × 8–11 µm) compared to P. subcubensis (typically 9–12 × 6–7 µm). ITS barcoding may not reliably separate them; multi-locus molecular data are recommended for confident identification. Mislabelling between the two is a documented problem in herbaria. Both species produce psilocybin.
Is the clinical research on psilocybin the same as research on Psilocybe cubensis?
No — and this distinction is important. The vast majority of published human clinical trials use pharmaceutical-grade synthetic psilocybin, not whole P. cubensis fruiting bodies. Extrapolating clinical outcomes from synthetic psilocybin to whole mushroom consumption involves assumptions about dose equivalence, minor alkaloid contributions (baeocystin, norbaeocystin), and preparation variables. A Phase 2a randomised trial using 3 g of standardised psilocybin mushrooms is currently ongoing (NCT06898606) but results have not been published. Clinical claims should attribute evidence to the psilocybin molecule, not to the species as a whole.
Are all "magic mushrooms" the same species?
No. "Magic mushrooms" is a colloquial term applied to any psilocybin-containing mushroom; over 200 species across multiple genera produce psilocybin, including Psilocybe, Panaeolus, Gymnopilus, and others. Psilocybe cubensis is the most widely cultivated and best-studied, but is one species among many. Regional names like "gold caps" or "golden teacher" are specific to P. cubensis strains, while "blue meanie" refers to both a P. cubensis strain and to Panaeolus cyanescens — a different species entirely. Species-level identification matters for safety as well as potency.